Radio and PodcastRadio and PodcastLive Radio & Podcasts
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) artwork
Science & Medicine

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Dec 16, 20224:00Science & Medicine

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

About This Episode

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Resear...

Podcast

This episode belongs to FDA Drug Safety Podcasts.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Dec 16, 2022, 4:00 long, audio available.

Related Episodes

Continue listening to more episodes from FDA Drug Safety Podcasts.